Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

Sha, Xuan; Dai, Yue; Chong, Lijuan; Wei, Min; Xing, Mengyuan; Zhang, Chun; Li, Jingjing

doi:10.1186/s12951-022-01720-2

Cited by 18 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the plaque area was differentially reduced in the ApoE −/− mice with treatments, compared with the Model group. Compared with the free Evol group (~ 13.33%) and Lipo@E NPs group (~ 12.44%), (Lipo + M)@E NPs showed the strongest inhibitory effect on aortic plaque formation with plaque area of ~ 3.78% (Fig.7B&C), which was consistent with previous reports [ 38 ]. This result demonstrated that this biomimetic nanoparticle could actively target, accumulate and penetrate into plaque.…”

Section: Resultssupporting

confidence: 91%

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

Zhu

Liu

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration of VSMCs play key roles in accelerating atherosclerosis. In this study, by utilizing the significant advantages of nano-materials, a biomimetic nanoliposome loading with Evolocumab (Evol), a PCSK9 inhibitor, was designed to alleviate atherosclerosis. In vitro results showed that (Lipo + M)@E NPs up-regulated the levels of α-SMA and Vimentin, while inhibiting the expression of OPN, which finally result in the inhibition of the phenotypic transition, excessive proliferation, and migration of VSMCs. In addition, the long circulation, excellent targeting, and accumulation performance of (Lipo + M)@E NPs significantly decreased the expression of PCSK9 in serum and VSMCs within the plaque of ApoE−/− mice.

show abstract

Section: Resultssupporting

confidence: 91%

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

Zhu

Liu

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Macrophage membrane was obtained according to the previously reported method [ 34 ] [ 35 ]. The obtained macrophage membrane was repeatedly extruded 10 times in PBS buffer through the polycarbonate porous membrane of 800 and 400 nm with an Avestin Mini-extruder, and the obtained vesicles of macrophage membrane were stored at 4 ℃.…”

Section: Methodsmentioning

confidence: 99%

Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles

Chong,

Jiang,

Wang

et al. 2023

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Anti-tumor M1-like and pro-tumor M2-like tumor-associated macrophages (TAMs) coexist in tumor microenvironments (TME). The adverse effects of these M1/M2 subsets on tumors directly affect the current strategies to improve anti-tumor immune response. Therefore, it has attracted great attention to change the tumor immunosuppressive microenvironment by reprogramming TAMs. In this paper, we constructed biomimetic nanoparticles (HMMDN-Met@PM) targeting M2-like TAMs for macrophage re-polarization. In detail, the core of the biomimetic nanoparticles is metformin-loaded hollow mesoporous manganese dioxide nanoparticles (HMMDN-Met). Benefited from the hollow and porous structure of HMMDN, metformin, the regulator of M1/M2 adopted in this work, can be easily and widely loaded into HMMDN. Moreover, macrophage membranes were utilized for HMMDN-Met coating (HMMDN-Met@MM) to prevent the premature drug leakage and provide specific molecular recognition/TME targeting. In addition, M2 macrophage targeting peptide (M2pep) was modified on the surface of macrophage membrane to specifically deliver the drug to M2-like TAMs to promote the polarization of M2 to M1 macrophages. Through in vitro and in vivo studies, we found that the expression of surface markers and inflammatory factors CD206, Arg-1 and IL-10 of type M2 macrophages decreased, while the surface markers of type M1 macrophages and the expression of inflammatory factors CD80, TNF-α and iNOS increased, indicating the successful re-polarization of M2 macrophages and finally realizing the inhibition of tumor growth. At the same time, under the acidic and GSH conditions of tumor, HMMDN was decomposed into Mn2+, which is a contrast agent for magnetic resonance imaging, thus realizing the tracking of tumor. This work practices biomimetic nanosystem in targeted imaging and immunotherapy, paving the way for strategy designing for tumor inhibition.

show abstract

“…MM@Lips-SHP1i NPs would battle macrophages in the plaque site in vivo to interact with oxidized low-density lipoprotein and LPS, decrease the intake of fresh lipids by macrophages, and decrease the production of foam cells. 487 …”

Section: Nanotechnology In Non-infectious Inflammatory Diseasesmentioning

confidence: 99%

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Huang,

Guo,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Inflammation-associated diseases encompass a range of infectious diseases and non-infectious inflammatory diseases, which continuously pose one of the most serious threats to human health, attributed to factors such as the emergence of new pathogens, increasing drug resistance, changes in living environments and lifestyles, and the aging population. Despite rapid advancements in mechanistic research and drug development for these diseases, current treatments often have limited efficacy and notable side effects, necessitating the development of more effective and targeted anti-inflammatory therapies. In recent years, the rapid development of nanotechnology has provided crucial technological support for the prevention, treatment, and detection of inflammation-associated diseases. Various types of nanoparticles (NPs) play significant roles, serving as vaccine vehicles to enhance immunogenicity and as drug carriers to improve targeting and bioavailability. NPs can also directly combat pathogens and inflammation. In addition, nanotechnology has facilitated the development of biosensors for pathogen detection and imaging techniques for inflammatory diseases. This review categorizes and characterizes different types of NPs, summarizes their applications in the prevention, treatment, and detection of infectious and inflammatory diseases. It also discusses the challenges associated with clinical translation in this field and explores the latest developments and prospects. In conclusion, nanotechnology opens up new possibilities for the comprehensive management of infectious and inflammatory diseases.

show abstract

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

Cited by 18 publications

References 45 publications

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Contact Info

Product

Resources

About